PMID- 35116347
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220205
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 10
IP  - 11
DP  - 2021 Nov
TI  - Treatment beyond progression with chemo-immunotherapy in an advanced esophageal 
      squamous cell carcinoma patient: a case report.
PG  - 4973-4978
LID - 10.21037/tcr-21-1395 [doi]
AB  - Esophageal cancer is an aggressive and common malignancy in Asian countries. Due 
      to late diagnosis and limited treatments, the prognosis of esophageal cancer is 
      still very poor. Although immune checkpoint inhibitors have become promising 
      second-line treatments for esophageal cancer, there are limited evidences for 
      first-line treatments. Here, we reported a case of successful treatment beyond 
      progression with chemo-immunotherapy for esophageal squamous cell carcinoma 
      (ESCC). Combined with local resection of several metastases during 
      chemo-immunotherapy, the patient achieved a long survival time of 22 months and a 
      good quality of life. Samples of the primary tumor and three metastases of 
      testicle, skin nodule and left adrenal were obtained to perform whole exome 
      sequencing (WES), RNA sequencing and immunohistochemistry. The skin nodule 
      metastasis was resected after partial response, while the other two metastases of 
      testicle and adrenal gland were removed after disease progression. 
      Immunohistochemistry results exhibited low/negative PD-L1 expression and WES 
      results showed intermediate TMB and MSI-L for all three lesions. However, RNA 
      sequencing results presented a higher percentage of infiltrating CD8(+) T cells, 
      higher signature scores of T cell status and higher expression level of human 
      leukocyte antigen (HLA) genes in skin nodule metastasis than the other two 
      metastases. This case provided a clinical evidence of beneficial treatment beyond 
      progression with chemo-immunotherapy for ESCC. In addition, tumor 
      microenvironment might be essential for clinical responses at the sampling time 
      point.
CI  - 2021 Translational Cancer Research. All rights reserved.
FAU - Peng, Ping
AU  - Peng P
AD  - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Xiao, Yajie
AU  - Xiao Y
AD  - YuceBio Technology Co., Ltd., Shenzhen, China.
FAU - Zhao, Zhikun
AU  - Zhao Z
AD  - YuceBio Technology Co., Ltd., Shenzhen, China.
FAU - Sun, Chao
AU  - Sun C
AD  - YuceBio Technology Co., Ltd., Shenzhen, China.
FAU - Wu, Dongfang
AU  - Wu D
AD  - YuceBio Technology Co., Ltd., Shenzhen, China.
FAU - Chen, Yuan
AU  - Chen Y
AD  - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
LA  - eng
PT  - Case Reports
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8798522
OTO - NOTNLM
OT  - Esophageal squamous cell carcinoma (ESCC)
OT  - case report
OT  - chemo-immunotherapy
OT  - treatment beyond progression
OT  - tumor microenvironment
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at https://dx.doi.org/10.21037/tcr-21-1395). PP, YC, and LZ 
      report that since the initial planning of the work, this study was funded by the 
      Wu Jieping Medical Foundation (320.6750.19078), Chinese Society of Clinical 
      Oncology Foundation (Y-BMS2019-070) and Hubei Provincial Natural Science 
      Foundation of China (grant No. 2019CFB544). No other funding or supports were 
      obtained for the past 36 months. The other authors have no conflicts of interest 
      to declare.
EDAT- 2022/02/05 06:00
MHDA- 2022/02/05 06:01
PMCR- 2021/11/01
CRDT- 2022/02/04 05:48
PHST- 2021/07/23 00:00 [received]
PHST- 2021/10/15 00:00 [accepted]
PHST- 2022/02/04 05:48 [entrez]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/02/05 06:01 [medline]
PHST- 2021/11/01 00:00 [pmc-release]
AID - tcr-10-11-4973 [pii]
AID - 10.21037/tcr-21-1395 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2021 Nov;10(11):4973-4978. doi: 10.21037/tcr-21-1395.